Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition

 
• By Jessica Merrill
  
Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer Inc.
Pfizer's Mikael Dolsten is leaving the company • Source: Pfizer (WENDY BARROWS photography)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Leadership

More from Scrip